The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Structural basis of PROTAC cooperative recognition for selective protein degradation
Open accessAbstract
Inducing macromolecular interactions with small molecules to activate cellular signaling is a challenging goal. PROTACs (proteolysis-targeting chimeras) are bifunctional molecules that recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degradation. Structural elucidation of the key ternary ligase-PROTAC-target species and its impact on target degradation selectivity remain elusive. We solved the crystal structure of Brd4 degrader MZ1 in complex with human VHL and the Brd4 bromodomain (Brd4 BD2). The ligand folds into itself to allow formation of specific intermolecular interactions in the ternary complex. Isothermal titration calorimetry studies, supported by surface mutagenesis and proximity assays, are consistent with pronounced cooperative formation of ternary complexes with Brd4 BD2. Structure-based-designed compound AT1 exhibits highly selective depletion of Brd4 in cells. Our results elucidate how PROTAC-induced de novo contacts dictate preferential recruitment of a target protein into a stable and cooperative complex with an E3 ligase for selective degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, the cooperativity of a bifunctional proximity inducer system is attributable to the ligand-induced protein–protein interface37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“In previous studies of bifunctional proximity inducers, a cooperativity term (represented by α) has been used to characterize the effects of protein–protein interaction in ternary complex formation36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“When plotted on a logarithmic scale, the MG dose-response curve has a familiar sigmoid shape (Fig. 7c), which is in stark contrast to the bell-shaped dose-response curve produced by the bifunctional proximity inducers36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“Several mechanisms have been shown to contribute to this increase in selectivity. This includes steric incapability of some targets to form a productive ternary complex, or lack of a suitably positioned lysine residue for ubiquitination.62−69”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [63]
In the citing paper
“It is widely believed that degraders uncouple efficacy from target occupancy (Gadd et al., 2017; Nowak et al., 2018; Olson et al., 2018; Roy et al., 2019).”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Gadd et al., 2017
In the citing paper
“An essential step in targeted protein degradation is the drug-induced formation of a ternary complex10,43.”
From Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders (2023) · cites this paper as [10]
In the citing paper
“While there have been several published crystal structures of ternary complexes 35, 52, 54, there are not yet enough to allow for a thorough and rigorous evaluation of our method.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“The observation that many effective PROTACs exhibit cooperativity in assembling the components of the ternary complex 35, 52, 53 implies the presence of adventitious favorable interactions between the target protein and the E3 ligase in the ternary complex.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“Cooperativity plays a role in the efficiency of the VHL–BRD4 degrader MZ1 (ref.129), but is dispensable for CRBN–BRD4 degraders130.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Scalable molecular dynamics with NAMD
Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., & Schulten, K. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20289 · Cited by 16,914
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
CHARMM: The biomolecular simulation program
Brooks, B. R., Brooks, C. L., MacKerell, A. D., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., et al. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21287 · Cited by 9,115
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,415
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,001
Design and synthesis of JNK1-targeted PROTACs and research on the activity
Guo, Y., Liu, F., Chi, M., Qian, H., Zhang, Y., Yuan, Y., Hou, S., Chen, X., & Ma, L. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108044 · Cited by 4
Yarawsky, A. E., Ronau, J. A., Thibaudeau, T. A., Ehlinger, A. C., Chhor, G., Hyman, S. M., Estrada, M. A., Stojkovic, V., DeLion, M. T., Vasudevan, A., et al. (2025) · European Biophysics Journal · doi:10.1007/s00249-025-01735-1 · Cited by 4
Schnatwinkel, J., Stein, R. R., Salcius, M., Wong, J. L., Chen, S., Fouché, M., & ROTH, H. ‐. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072936 · Cited by 4
Zhang, Z., Yuan, S., Xu, S., Guo, D., Chen, L., Hou, W., & Wang, M. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00311-5 · Cited by 4
Ingersoll, J., Shcherbakov, A. A., Vaish, A., & Poppe, L. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00198 · Cited by 4
ProxyBind: A compendium of binding sites for proximity-induced pharmacology
Rovers, E., Liu, L., & Schapira, M. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.11.010 · Cited by 3
Jiang, W., & Soutter, H. H. (2024) · Journal of Visualized Experiments · doi:10.3791/65718 · Cited by 2
PROTACs improve selectivity for targeted proteins
Liu, L., Guan, X., Zhuo, J., Wu, X., & Han, X. (2025) · Acta Materia Medica · doi:10.15212/amm-2025-0015 · Cited by 3
Targeted Protein Degradation for Agricultural Applications: Rationale, Challenges, and Outlook
Fourches, D., Pilotte, J. R., Watts, B. E., Saltzberg, D. J., & Cicchillo, R. M. (2025) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.5c00111 · Cited by 3
Modular Assembled Targeting Chimera Enables Multimodal Targeted Protein Degradation
Zhu, W., Zhang, W., Wang, Y., Chen, J., Xu, F., & Pang, J. (2025) · JACS Au · doi:10.1021/jacsau.5c01131 · Cited by 3
Su, X., Tong, Y., Zanon, P. R. A., Wang, J., Tanaka, T., Childs‐Disney, J. L., & Disney, M. D. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c14363 · Cited by 3
Targeting the Spliceosomal Protein USP39 Through Allosteric Ligands and PROTAC‐Induced Degradation
Schäfer, D., Prieto‐Garcia, C., Wang, J., Heinz, M., Matković, V., Kielkowski, P., Hasselbeck, S., Shah, V. J., Knapp, S., Hummer, G., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202516809 · Cited by 3
Bao, Y., Zhu, Y., Wei, X., Fang, Y., Zhu, J., Gao, F., Dong, G., He, S., & Sheng, C. (2025) · Advanced Science · doi:10.1002/advs.202520975 · Cited by 3
Expanding the toolbox to develop IAP-based degraders of TEAD transcription factors
Gupta, N., Trainor, N. B., Radwan, M., Nguyen, S., Duncan, L. J., Tang, A. X., Beveridge, J. G., Silke, N., Yousef, J. M., Bilgilier, C., et al. (2026) · Communications Chemistry · doi:10.1038/s42004-025-01871-x · Cited by 3
Yang, T., Hu, Y., Guo, A., Zhang, X., Wang, W., Yi, L., Zhang, R., Gou, X., Qian, Z., Wang, B., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02542-y · Cited by 3
Discovery of KRAS-G12D degraders via exploration of various E3 ligases
Yim, H., Song, X., Zhong, Y., Hu, J., Xiong, Y., & Jin, J. J. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118635 · Cited by 3
Sriram, S., Krishnakumar, P., & Sudandiradoss, C. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1745654 · Cited by 3
Advantages of PROTACs in achieving selective degradation of homologous protein families
Yang, L., Mao, X., Zhang, J., Shu, J., Huang, W., Dong, X., Chen, Y., & Wu, M. (2026) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.22.49 · Cited by 3
Lu, X., Qin, J., Dong, S., Yuan, Y., Zhang, Z., Zhang, B., Chen, X., Gan, X., Liang, H., & Liu, F. (2026) · Biomarker Research · doi:10.1186/s40364-026-00937-9 · Cited by 3
The importance of controls in targeted protein degradation: Determining mechanism
Hill-Payne, B., Dilones, S., & Burslem, G. M. (2022) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2022.10.006 · Cited by 3
Advancing brain tumor therapy: unveiling the potential of PROTACs for targeted protein degradation
Ibrahim, S., Khan, M. U., Noreen, S., Firdous, S., Khurram, I., Rehman, R., Javed, M. A., & Ali, Q. (2025) · Cytotechnology · doi:10.1007/s10616-025-00716-8 · Cited by 3
Schiedel, M., Moroglu, M., Ascough, D. M. H., Chamberlain, A. E. R., Kamps, J. J. A. G., Sekirnik, A. R., & Conway, S. J. (2019) · Angewandte Chemie · doi:10.1002/ange.201812164 · Cited by 3
Structural and Biophysical Principles of Degrader Ternary Complexes
Zollman, D., & Ciulli, A. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00014 · Cited by 3
Self-citationMcConnell, D. B. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00115 · Cited by 3
Bondeson, D. P., Smith, B. E., & Buhimschi, A. D. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_7 · Cited by 3
Main Approaches to Controlled Protein Degradation in the Cell
Kapitonova, M. A., Shadrina, O., Korolev, S. P., & Gottikh, M. (2021) · Molecular Biology · doi:10.1134/s0026893321030067 · Cited by 3
Early inhibition of BRD4 facilitates iPSC reprogramming via accelerating rDNA dynamic expression
Zhang, Z., Hu, X., Sun, Y., Lei, L., & Liu, Z. (2024) · BMC Biology · doi:10.1186/s12915-024-01997-9 · Cited by 3
Fabbrizi, E., Fiorentino, F., Casano, F., Mai, A., & Rotili, D. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2486146 · Cited by 3
Bromodomains: Promising Targets for Drug Discovery
Pervaiz, M., Mishra, P., & Günther, S. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527809257.ch13 · Cited by 3
Facile Synthesis of Homodimeric Protein Ligands
Gui, W., & Kodadek, T. J. (2023) · ChemBioChem · doi:10.1002/cbic.202300392 · Cited by 3
Proteolysis-Targeting Chimeras: A Kaleidoscope of Targeted Protein Degradation
Mou, Y., Wen, S., Gao, X., & Jiang, Z. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0199 · Cited by 3
Trivalent PROTACs Enhance Protein Degradation Through Cooperativity and AvidityPreprint
Imaide, S., Riching, K. M., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N. B., Mahan, S. D., Murphy, N., Chan, K.-H., Testa, A., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13218695.v1 · Cited by 3
Self-citationBenchmarking of PROTAC docking and virtual screening toolsPreprint
Rovers, E., & Schapira, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.30.555318 · Cited by 3
Yan, H., Zang, R., Cui, T., Liu, Y., Zhang, B., Zhao, L., Li, H., Zhou, J., Wang, H., Zeng, Q., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03910-1 · Cited by 2
A Kinetic Scout Approach Accelerates Targeted Protein Degrader Development
Fan, A. T., Gadbois, G. E., Huang, H., Chaudhry, C., Jiang, J., Sigua, L. H., Smith, E. R., Wu, S., Poirier, G. J., Dunne-Dombrink, K., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202417272 · Cited by 2
Rosignoli, S., Giordani, S., Pacelli, M., Guarguaglini, G., & Paiardini, A. (2025) · Biomolecules · doi:10.3390/biom15020206 · Cited by 2
Pierri, M., Bove, G., Gazzillo, E., Colarusso, E., Scala, F., Pepe, G., Terracciano, S., Chini, M. G., Simonelli, N., Bruno, I., et al. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202404218 · Cited by 2
Unraveling the secrets of novel PROTACs to improve degradation efficacy
Huang, J., Yang, X., Huang, Q., Gao, Y., Bandaranayake, P. C. G., Kandegama, W. M. W. W., Ashby, C. R., Dong, Y., Wang, Z., & Hao, G. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11273-9 · Cited by 3
Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader
Orsi, D. L., Lazarski, K. E., Improgo, R., Agafonov, R. V., Ahn, J. Y., Baddour, J., Cassidy, K. B., Chaturvedi, P., Cole, K. S., Deibler, R. W., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00337g · Cited by 2
Chromatin Regulatory Targets for Anticancer Therapeutics
Barta, P. A., Carter, T. R., & Erb, M. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00231 · Cited by 2
Gong, L., Li, S., Sun, J., Liu, K., Wang, S., Ji, M., Hou, P., Li, Y., Yang, D., & Liu, D. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.002 · Cited by 2
Sternicki, L. M., Crowe, C., Wieske, L. H. E., Ciulli, A., & Poulsen, S. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c01970 · Cited by 3
Self-citationDu, J., Villemure, E., Johnson, M., Azumaya, C. M., Gaspar, C. J., Marsters, S. A., Lawrence, D. A., Foster, S. A., Rohou, A. L., Cheung, T. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66382-8 · Cited by 2
Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs
Hu, L., Wu, S., Wang, W., He, H., Che, J., Wu, M., & Dong, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118499 · Cited by 4
Post‐Covid Alzheimer and Its Remediation via PROTACs Therapy: A Comprehensive Review
Bhowmick, T., Basu, R., Mitra, A. K., Ali, S. A., Kumer, A., & Dhara, B. (2025) · Health Science Reports · doi:10.1002/hsr2.71631 · Cited by 2
Lu, X. Y., Song, S., Qiu, F., Zhang, H., Shi, J., & Wang, B. (2026) · ACS Nano · doi:10.1021/acsnano.5c19999 · Cited by 2
Wei, Q., Zhang, J., Chen, J., Cai, X., 周金培, Wang, B., Zhang, H., & Cao, P. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118667 · Cited by 2
The Multifaceted Legacy of Thalidomide: Chemistry and Biology Driving Modern Drug Design
Nikovia, K., Kapsalis, M., Georgoulakis, M., Panousis, A., & Neochoritis, C. G. (2026) · ChemMedChem · doi:10.1002/cmdc.202501105 · Cited by 2
Wang, X., Song, J., Zhao, Y., Li, W., Li, J., Xu, X., Liu, W., Tao, F., & Xu, Y. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108239 · Cited by 2
SE(3)-PROTACs: Geometric deep learning for PROTAC degradation prediction
Kothakapu, A. R., Madugula, S., Gandeed, S. B. S., Yadlapati, K. S. S., Sury, S., & Kondaparthi, V. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag228 · Cited by 2
Molecular glues and PROTACs: unlocking targeted protein degradation in plant biology
Donderis-Fagoaga, C., Orea-Ordóñez, L., & Lozano‐Juste, J. (2026) · Journal of Experimental Botany · doi:10.1093/jxb/erag256 · Cited by 2
Su, G., Wang, Y., & Yao, L. (2026) · Pharmaceuticals · doi:10.3390/ph19070988 · Cited by 2
Targeted protein degradation: bridging chemical biology and clinical translation
Zhang, Y., Fu, J.-W., Liu, Y., Wu, R. Y., Liang, Y., Zhang, W., Yuan, T., Zhu, H., He, Q.-J., & Yang, B. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01861-2 · Cited by 2
Evolving CRBN ligands enhance the drug-like properties of protein degraders
Ji, X.-Q., Wang, L., & Dai, X. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2700038 · Cited by 2
Paras, G., & Schweizer, M. T. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.07.014 · Cited by 2
Qin, S., Peng, R., Zhang, G., Yan, S., Xiao, J., Liu, Z., Tan, Z., Xie, Q., Li, S., Luo, W., et al. (2026) · Smart Molecules · doi:10.1002/smo2.70089 · Cited by 2
Proteome editing using engineered proteins that hijack cellular quality control machinery
Lopez‐Barbosa, N., Ludwicki, M. B., & DeLisa, M. P. (2019) · AIChE Journal · doi:10.1002/aic.16854 · Cited by 2
Peng, C., Sun, C., Wang, N., He, Y., Xu, J., Deng, Y., Gao, L., Zhong, J., Xiong, X., & Liu, L. (2019) · Bioscience Reports · doi:10.1042/bsr20190828 · Cited by 2
Targeted Protein Degradation by Proteolysis Targeting Chimeras
Du, W. (2022) · Wiley eBooks · doi:10.1002/9781119627784.ch11 · Cited by 2
Biochemical Principles of Targeted Protein Degradation
Agafonov, R. V., Deibler, R. W., Elam, W. A., Patel, J. S., & Fisher, S. L. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch10 · Cited by 2
Combining AI and traditional screening for discovery of a potent ROCK2 inhibitor against lymphoma
Lu, Y., Shen, Z., Shen, L., Ying, J., Gao, J., Zhao, J., Geng, S., Chi, X., Zhang, T., Xu, L., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.137394 · Cited by 2
Su, Z., Yin, S., & Wu, Y. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c06497 · Cited by 2
Olp, M. D., Cui, H., Pomerantz, W. C. K., & Smith, B. C. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016544-00209 · Cited by 2
Основные подходы к контролируемой деградации белков в клетке
Kapitonova, M. A., Shadrina, O., Korolev, S. P., & Gottikh, M. (2021) · Molecular Biology · doi:10.31857/s0026898421040066 · Cited by 2
Du, W. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0147 · Cited by 2
Modeling the Structures of Ternary Complexes Mediated by Molecular Glues
Drummond, M. L. (2024) · Wiley eBooks · doi:10.1002/9783527840748.ch22 · Cited by 2
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–2
Muñoz‐Torrero, D., Mangoni, A. A., Liu, H., Hulme, C., Rautio, J., Karaman, R., Sousa, E., Prókai-Tátrai, K., Sabatier, J., Siciliano, C., et al. (2017) · Molecules · doi:10.3390/molecules23010065 · Cited by 2
Proximity Biosensor Assay for PROTAC Ternary Complex AnalysisPreprint
Ponzo, I., Soldà, A., Crowe, C., Dahl, G., Geschwindner, S., Ciulli, A., & Rant, U. (2024) · ChemRxiv · doi:10.26434/chemrxiv-2024-8w4zb · Cited by 2
Self-citationSpecific degrader for fusion oncokinase kills tumors and is augmented by bimodal degrader-siRNAPreprint
Shirani, M., Bowie, R. S., Tomasini, M. D., Hook, R., Ng, D., Shebl, B., Lyons, B. A., Coffino, P., & Simon, S. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.24.650501 · Cited by 2
Effective Tubulin Degradation by Rationally Designed Proteolysis Targeting ChimerasPreprint
Maiocchi, A., Abel, A., Basellini, M. J., Pérez‐Peña, H., Boiarska, Z., Ferrandi, E. E., Kozicka, Z., Fasano, V., Pieraccini, S., Cappelletti, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.22.655572 · Cited by 2
A cell-based degrader assessment platform facilitates discovery of functional NUDT5 PROTACsPreprint
Alam, S., Pires, M. J. A. A. S., Tidestav, G., Jemth, A., Eklund, J., Klingegård, F., Caraballo, R., Gaetani, M., Rotili, D., van den Elzen, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.13.659494 · Cited by 2
The future of covalent inhibition
Keserű, G. M., & Erlanson, D. A. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.10.003 · Cited by 1
Pilania, P., Nandi, S., Meena, D. K., & Sharma, B. K. (2024) · Current Signal Transduction Therapy · doi:10.2174/0115743624279638240211170045 · Cited by 1
Diehl, C. J., Salerno, A., & Ciulli, A. (2024) · Angewandte Chemie · doi:10.1002/ange.202319456 · Cited by 1
Self-citationTargeting Epigenetic Readers Using Small Molecule Binders and PROTAC Degraders
Boccia, E., Gazzillo, E., Chini, M. G., Bifulco, G., & Lauro, G. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_240 · Cited by 1
Exploring the Role of PROTACs for the Treatment of Breast Cancer
Pannu, A. S., Goyal, R. K., & Goswami, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_12 · Cited by 1
Jean-Francois, F. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00010-3 · Cited by 1
Advancing proteolysis targeting chimeras toward clinical drug developments
Tian, X., Huang, C., Yin, L., & Yu, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00007-8 · Cited by 1
Computational approaches to aid PROTAC drug discovery
Chakraborti, S., & McAulay, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00004-2 · Cited by 1
Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer
Zhao, K., Zhang, J., Yang, Z., Wang, R., Shi, Y., Ji, Y., Zhang, S., & Liu, M. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s527906 · Cited by 1
Molecular Degraders: A Comprehensive Review of Small Molecule Induced Protein Degradation Strategies
Sindhwani, D., Arora, K., kumar, P., Verma, P. K., & Bhosale, V. V. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037355750250526052851 · Cited by 1
Transcription factor degraders
Wang, M., Wei, Y., & Ma, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21816-3.00006-3 · Cited by 1
Design of Tissue-Selective PROTACs Through Recruiting E3 Ligase Scaffolding Protein MAGEA11
Jacobsen, I. E., Shi, R., Scholtz, C. R., Pomerantz, W. C. K., & Georg, G. I. (2026) · npj Drug Discovery. · doi:10.1038/s44386-026-00081-2 · Cited by 1
Developmental toxicology profile of the IRAK4 degrader KT-474
Enerson, B. E., Cappon, G. D., Shi, Y., Walther, D. M., Campbell, V., Chen, D., Kuhn, E. W., Massa, V., Ho, C. M. W., Zheng, X., et al. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf170 · Cited by 1
Interface Architecture of a VHL-PROTAC Complex with and without Cullin-2
Whitford, E. N., Gilbert, J. D., Kostelic, M. M., Ehlinger, A. C., Thibaudeau, T. A., McLoughlin, S. M., & Wysocki, V. H. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c01509 · Cited by 1
Design, modelling, and pharmacokinetic prediction of novel BRD4-targeting PROTACs
Bharath, B. R., Jahnavi, S., & Khan, N. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100169 · Cited by 1
Guo, L.-N., Li, Y.-H., Zhu, R.-Y., Su, N., Shao, Z.-Y., & Diao, H. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md01003a · Cited by 1
Furuhata, T., Yoshida, K., 凌嘉, 藤., Miyamoto, J., Moriyama, C., Masuda-Ozawa, T., Tsuchiya, H., Saeki, Y., & Okamoto, A. (2026) · Communications Chemistry · doi:10.1038/s42004-026-01895-x · Cited by 1
Diao, J., Jing, H., Lin, X., Wang, Y., Lu, Y., Xu, L., Xiong, C., Zhang, A., Meng, L., Zhang, X., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118675 · Cited by 1
Expanding The Scope of AKT Modulation Through Targeted Protein Degradation
Serafini, M., & Moreira, R. (2026) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2026.157 · Cited by 1
Bidirectional regulation of the ubiquitin-RNA modification axis in cancer
Li, K., Bao, L., Jiang, B., & Jin, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1761698 · Cited by 1
Tewari, A., Pawar, A. B., & Roy, S. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100372 · Cited by 1
Engstrom, A., Vasta, J. D., Robers, M. B., & Lokey, R. S. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00871 · Cited by 1
A destination-driven framework for nanoparticle-enabled targeted protein degradation
Wang, Y., Xia, X., Xie, S., Tong, F., Liu, W., & Gao, H. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.05.009 · Cited by 1
Abdelsalam, M. A. M., Halilovic, M., Ashry, R., Nassar, H., Erdmann, F., Schmidt, M., Krämer, O. H., & Sippl, W. (2026) · Pharmaceuticals · doi:10.3390/ph19050756 · Cited by 1
Gu, J., He, M., Wang, W., Hu, J., Yang, X., Lai, M., Li, S., Duan, X., Luo, Q., & Zhang, G. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105384 · Cited by 1
Wang, Q., Li, R., & Zhang, H. (2026) · Biomedical Chromatography · doi:10.1002/bmc.70498 · Cited by 1
Recent progress of PROTACs in cancer immunotherapy
Liu, P., Chen, Q., & Li, J. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110042 · Cited by 1
Liu, M., Song, Y., Luo, K., Zhao, Y., & Zhang, H. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105430 · Cited by 2
Multicomponent Stapling of Glucagon‐Like Peptide‐1 Enables Receptor‐Guided PROTAC Delivery
Venne, J. L., Krajčovičová, S., Davies, G., Bolt, H., Revell, J. D., & Spring, D. R. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.9595531 · Cited by 1
Metadata
- Authors
- Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Ciulli, Alessio
- Venue
- Nature Chemical Biology
- Published
- 2017-03-13
- Volume
- 13
- Issue
- 5
- Pages
- 514-521
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC5392356
- OpenAlex
- W2597078857
- Cited by
- 1,242
- References
- 60
- Citations by year
- 2026: 173 · 2025: 173 · 2024: 176 · 2023: 159 · 2022: 138 · 2021: 129 · 2020: 133 · 2019: 86 · 2018: 46 · 2017: 26
- FWCI
- 33.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Lancaster EPrints (Lancaster University) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- Funders
- Wellcome Trust (100476, 094090/Z/10/Z, 094090, 100476/Z/12/Z)
- Diamond Light Source (MX10071)
- European Commission (H2020-MSCA-IF-2014, H2020- MSCA-IF-2015, H2020, 655516, H2020‐MSCA‐IF, H2020-MSCA)
- Directorate for Biological Sciences
- Horizon 2020 Framework Programme (H2020‐MSCAIF‐2014, H2020-MSCA, MSCA-IF-2014, H2020-MSCA-IF-2015)
- Medical Research Council
- Biotechnology and Biological Sciences Research Council (BB/J001201/1, BB/J001201/2)
- H2020 Marie Skłodowska-Curie Actions (H2020-MSCA-IF-2014, H2020-MSCA-IF-2014-655516, H2020, 655516, H2020-MSCA-IF, H2020-MSCA-IF-2015, H2020-MSCA, 806323, H2020-MSCA-IF-2015-806323)
- FP7 Ideas: European Research Council (311460)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, BRD4, VHL E3 ubiquitin ligase, bromodomain, selective protein degradation, crystal structure, ternary complex, structure-based drug design, ubiquitination
- MeSH terms
- Elongin, Bromodomain Containing Proteins, Amino Acid Sequence, Dipeptides, Heterocyclic Compounds, 3-Ring, Humans, Models, Molecular, Nuclear Proteins, Protein Binding, Protein Conformation, Structure-Activity Relationship, Thermodynamics, Transcription Factors, Crystallography, X-Ray, Cell Cycle Proteins, Ubiquitin-Protein Ligases, Multiprotein Complexes, Von Hippel-Lindau Tumor Suppressor Protein, Small Molecule Libraries, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
